Clinical Trial

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed for SCLC patients with refractory brain metastases or leptomeningeal metastasis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-05; most recent amendment 2024-09-17.
Trial Details
NCT Number NCT06497543
Lead Sponsor Hunan Province Tumor Hospital
Collaborators: Second People's Hospital of Hunan
Conditions Small-cell Lung Cancer
Enrollment 80 participants
Start Date 2024-10-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19